All In Biotech

Free tool

FAERS Monitor: Duetact

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 19, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021925 or its brand name (Duetact, Glimepiride, Pioglitazone Hydrochloride). Reports on generic versions are filed under their own applications.

Reports

93

Serious

48

52% of reports

Hospitalization

16

Death reported

8

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • blood glucose increased9
  • bladder cancer8
  • drug ineffective8
  • dyspnoea7
  • nausea7
  • vomiting6
  • depression5
  • dizziness5
  • flushing5
  • malaise5
  • anxiety4
  • asthenia4
  • cough4
  • diarrhoea4
  • oedema peripheral4

Reports by year received

View as table
YearReports
20074
200814
20097
20105
201116
20124
20133
20142
201514
20167
20182
20194
20203
20211
20222
20233
20262

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,066 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
bladder cancerSignal830.715.8202
flushingSignal511.14.737
blood glucose increasedSignal910.85.871
oedema peripheralSignal47.42.816
depressionSignal55.02.112
coughSignal43.21.24
anxietySignal43.21.24
vomitingSignal62.91.36
dyspnoeaSignal72.81.47
malaise52.61.13
asthenia42.40.92
dizziness52.31.02
nausea72.01.03
diarrhoea41.40.50
drug ineffective81.40.71

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.